` FAE (Faes Farma SA) vs DAX Index Comparison - Alpha Spread

FAE
vs
DAX Index

Over the past 12 months, FAE has outperformed DAX Index, delivering a return of 28% compared to the DAX Index's 23% growth.

Stocks Performance
FAE vs DAX Index

Loading

Performance Gap
FAE vs DAX Index

Loading
FAE
DAX Index
Difference

Performance By Year
FAE vs DAX Index

Loading
FAE
DAX Index
Add Stock

Competitors Performance
Faes Farma SA vs Peers

DAX Index
FAE
LLY
JNJ
NOVO B
ROG
Add Stock

Faes Farma SA
Glance View

Market Cap
1.2B EUR
Industry
Pharmaceuticals

Faes Farma SA, a notable player in the pharmaceutical arena, has orchestrated its operations with the precision of a seasoned conductor. Rooted in Spain with an impressive international reach, the company blends research prowess with adept production capabilities. Central to its modus operandi is the development, manufacture, and commercialization of a wide range of pharmaceutical products and nutritional supplements. With science as its guiding star, Faes Farma dedicates substantial resources to research and development, ensuring a pipeline filled with innovative treatments that cater to diverse medical needs. The company has carved its niche by focusing on therapeutic areas such as allergy, dermatology, and the central nervous system, allowing it to create specialized solutions that resonate well with healthcare providers and patients alike. The company’s revenue engine is driven primarily by its robust product sales, enhanced by strategic partnerships and licensing agreements that bolster its market presence both in Spain and across global markets. Through rigorous production processes, Faes Farma ensures the delivery of high-quality medications, matching industry standards and fostering consumer trust. Additionally, its geographical diversification, with subsidiaries and distribution channels spreading across Europe, Latin America, and Africa, underpins its economic durability. By marrying innovation with strategic commercial tactics, Faes Farma has deftly navigated the complexities of the pharmaceutical landscape, ensuring not only profitability but also the sustained delivery of health-enhancing products to the global community.

FAE Intrinsic Value
3.2 EUR
Overvaluation 20%
Intrinsic Value
Price
F
Back to Top